- Home
- UCL vs TPST Comparison
UCL vs TPST Comparison
Compare UCL & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCL
- TPST
- Stock Information
- Founded
- UCL 2014
- TPST 2011
- Country
- UCL Hong Kong
- TPST United States
- Employees
- UCL N/A
- TPST N/A
- Industry
- UCL Telecommunications Equipment
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- UCL Consumer Discretionary
- TPST Health Care
- Exchange
- UCL Nasdaq
- TPST Nasdaq
- Market Cap
- UCL 49.7M
- TPST 40.4M
- IPO Year
- UCL 2020
- TPST N/A
- Fundamental
- Price
- UCL $1.25
- TPST $0.84
- Analyst Decision
- UCL
- TPST Strong Buy
- Analyst Count
- UCL 0
- TPST 3
- Target Price
- UCL N/A
- TPST $21.67
- AVG Volume (30 Days)
- UCL 81.9K
- TPST 636.7K
- Earning Date
- UCL 03-13-2025
- TPST 03-18-2025
- Dividend Yield
- UCL N/A
- TPST N/A
- EPS Growth
- UCL 169.91
- TPST N/A
- EPS
- UCL 0.11
- TPST N/A
- Revenue
- UCL $87,405,000.00
- TPST N/A
- Revenue This Year
- UCL $7.21
- TPST N/A
- Revenue Next Year
- UCL $15.05
- TPST N/A
- P/E Ratio
- UCL $10.74
- TPST N/A
- Revenue Growth
- UCL 4.73
- TPST N/A
- 52 Week Low
- UCL $0.97
- TPST $0.70
- 52 Week High
- UCL $3.30
- TPST $6.00
- Technical
- Relative Strength Index (RSI)
- UCL 43.51
- TPST 46.96
- Support Level
- UCL $1.19
- TPST $0.77
- Resistance Level
- UCL $1.50
- TPST $0.85
- Average True Range (ATR)
- UCL 0.09
- TPST 0.05
- MACD
- UCL 0.00
- TPST 0.00
- Stochastic Oscillator
- UCL 14.71
- TPST 59.46
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc provides mobile data connectivity and portable WiFi services. The business operates under uCloudlink 1.0, which focuses on cross-border travelers that need mobile data connectivity services across different countries. Under uCloudlink 2.0, provides mobile data connectivity services to local users across different MNOs in a single country. It generates revenue from the provision of data connectivity services, and the sales of terminals and sales of data related products.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.